Suppression and recovery of gonadotropin and steroid secretion by a gonadotropin-releasing hormone receptor antagonist in healthy women with normal ovulation versus women with polycystic ovary syndrome in the early follicular phase

Fertility and Sterility

Volumn 91, Issue 5, 2009, Pages 1857-1863

  Sagnella, Francesca ^a   Apa, Rosanna ^a   Guido, Maurizio ^a   Villa, Paola ^a   Spadoni, Valentina ^a   Miceli, Fiorella ^a   Lanzone, Antonio ^a,b  

^a CATHOLIC UNIVERSITY   (Italy)

^b OASI RESEARCH INSTITUTE IRCCS   (Italy)

Author keywords

cetrorelix; GnRH antagonist; GnRH receptors; polycystic ovary syndrome

Indexed keywords

ANDROSTENEDIONE; CETRORELIX; ESTROGEN; FOLLITROPIN; GONADORELIN ANTAGONIST; GONADOTROPIN; HYDROXYPROGESTERONE; LUTEINIZING HORMONE; STEROID; TESTOSTERONE;

ADULT; ANDROSTENEDIONE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ESTROGEN BLOOD LEVEL; FEMALE; FOLLICULAR PHASE; GONADOTROPIN BLOOD LEVEL; GONADOTROPIN RELEASE; HUMAN; MENSTRUAL CYCLE; OVARY POLYCYSTIC DISEASE; OVULATION; PRIORITY JOURNAL; STEROID RELEASE; TESTOSTERONE BLOOD LEVEL;

17-ALPHA-HYDROXYPROGESTERONE; ADULT; ANDROSTENEDIONE; ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; FOLLICULAR PHASE; GONADAL STEROID HORMONES; GONADOTROPIN-RELEASING HORMONE; HUMANS; LUTEINIZING HORMONE; OVULATION; POLYCYSTIC OVARY SYNDROME; RECEPTORS, LHRH; TESTOSTERONE;

EID: 67349258559     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2008.02.120     Document Type: Article

References (38)

1. Homburg R. Polycystic ovary syndrome-from gynaecological curiosity to multisystem endocrinopathy. Hum Reprod 11 (1996) 29-39
2. Franks S. Polycystic ovary syndrome. N Engl J Med 333 (1995) 853-861
3. Kiddy D.S., Sharp P.S., White D.M., Scanlon M.F., Mason H.D., Bray C.S., et al. Differences in clinical and endocrine features between obese and non-obese subjects with polycystic ovary syndrome: an analysis of 263 consecutive cases. Clin Endocrinol 32 (1990) 213-220
4. Kiddy D.S., Hamilton-Fairley D., Seppala M., Koistinen R., James V.H., Reed M.J., et al. Diet-induced changes in sex hormone-binding globulin and free testosterone in women with normal and polycystic ovaries: correlation with serum insulin and insulin-like growth factor-I. Clin Endocrinol (Oxf) 31 (1989) 757-763
5. Pugeat M., Crave J.C., Elmidani M., Nicolas M.H., Garoscio-Cholet M., Lejeune H., et al. Pathophysiology of sex hormone binding globulin (SHBG): relation to insulin. J Steroid Biochem Mol Biol 40 (1991) 841-849
6. Sharp P.S., Kiddy D.S., Reed M.J., Anyaoku V., Johnston D.G., and Franks S. Correlation of plasma insulin and insulin-like growth factor-I with indices of androgen transport and metabolism in women with polycystic ovary syndrome. Clin Endocrinol 35 (1991) 253-257
7. Yen S.S.C., Vela P., and Rankin J. Inappropriate secretion of follicle-stimulating hormone and luteinizing hormone in polycystic ovarian disease. J Clin Endocrinol Metab 30 (1970) 435-442
8. Knobil E. The neuroendocrine control of the menstrual cycle. Recent Prog Horm Res 36 (1980) 53-88
9. Yen S.S. The polycystic ovary syndrome. Clin Endocrinol (Oxf) 12 (1980) 177-207
10. Karten M.J., and Rivier J.E. Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists: rationale and perspective. Endocr Rev 7 (1986) 44-66
11. Reissmann T., Felberbaum R., Diedrich K., Engel J., and Comaru-Schally A.V. Development and applications of luteinizing hormone-releasing hormone antagonists in the treatment of infertility: an overview. Hum Reprod 10 (1995) 1974-1981
12. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19 (2004) 41-47
13. Fulghesu A.M., Ciampelli M., Belosi C., Apa R., Pavone V., and Lanzone A. A new ultrasound criterion for the diagnosis of polycystic ovary syndrome: the ovarian stroma/total area ratio. Fertil Steril 76 (2001) 326-331
14. New M.I., Lorenzen F., Lerner A.J., Kohn B., Oberfield S.E., Pollack M.S., et al. Genotyping steroid 21-hydroxylase deficiency: hormonal reference data. J Clin Endocrinol Metab 57 (1983) 320-326
15. Pacini G., and Bergman R.N. MINMOD: a computer program to calculate insulin sensitivity and pancreatic responsivity from the frequently sampled intravenous glucose tolerance test. Comput Methods Programs Biomed 23 (1986) 113-122
16. Rebar R., Judd H.L., Yen S.S.C., Rakoff J., Vandenberg G., and Naftolin F. Characterization of the inappropiate gonadotropin secretion in polycystic ovary syndrome. J Clin Invest 57 (1976) 1320-1329
17. Taylor A.E., McCourt B., Martin K.A., Anderson E.J., Adams J.M., Schoenfeld D., et al. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. J Clin Endocrinol Metab 82 (1997) 2248-2256
18. Burger C.W., Korsen T., van Kessel H., van Dop P.A., Caron F.J.M., and Shoemaker J. Pulsatile hormone patterns in the follicular phase of the menstrual cycle, polycystic ovarian disease (PCOSD) and non-PCOSD secondary amenorrhea. J Clin Endocrinol Metab 61 (1985) 1126-1132
19. Imse V., Holzapfel G., Hinney B., Kuhn W., and Wuttke W. Comparison of luteinizing hormone pulsatility in the serum of women suffering from polycystic ovarian disease using a bioassay and five different immunoassays. J Clin Endocrinol Metab 74 (1992) 1053-1061
20. Batrinos M.L. Diagnostic dilemmas in polycystic ovarian syndrome. Ann N Y Acad Sci 687 (1993) 230-234
21. Barnes R.B., Rosenfield R.L., Burstein S., and Ehrmann D.A. Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome. N Engl J Med 320 (1989) 559-565
22. Tesarik J., and Mendoza C. Direct non-genomic effects of follicular steroids on maturing human oocytes: oestrogen versus androgen antagonism. Hum Reprod Update 3 (1997) 95-100
23. Lanzone A., Fulghesu A.M., Spina M.A., Apa R., Menini E., Caruso A., et al. Successful induction of ovulation and conception with combined gonadotropin-releasing hormone agonist plus highly purified follicle-stimulating hormone in patients with polycystic ovarian disease. J Clin Endocrinol Metab 65 (1987) 1253-1258
24. Patel K., Coffler M.S., Dahan M.H., Malcom P.J., Deutsch R., and Chang R.J. Relationship of GnRH-stimulated LH release to episodic LH secretion and baseline endocrine-metabolic measures in women with polycystic ovary syndrome. Clin Endocrinol 60 (2004) 67-74
25. Bramley T.A., Menzies G.S., and Baird D.T. Specific binding of gonadotropin-releasing hormone and an agonist to human corpus luteum homogenates: characterization, properties, and luteal phase levels. J Clin Endocrinol Metab 61 (1985) 834-841
26. Latouche J., Crumeyrolle-Arias M., Jordan D., Kopp N., Augendre-Ferrante B., Cedard L., et al. GnRH receptors in human granulosa cells: anatomical localization and characterization by auto radiographic study. Endocrinology 125 (1989) 1739-1741
27. Brus L., Lambalk C.B., de Koning J., Helder M.N., Janssens R.M., and Schoemaker J. Specific gonadotropin-releasing hormone analogue binding predominantly in human luteinized follicular aspirates and not in human pre-ovulatory follicles. Hum Reprod 12 (1997) 769-773
28. Ortmann O., Weiss J.M., and Diedrich K. Embryo implantation and GnRH antagonists: ovarian actions of GnRH antagonists. Hum Reprod 16 (2001) 608-611
29. Weiss J.M., Oltmanns K., Gürke E.M., Polack S., Eick F., Felberbaum R., et al. Actions of gonadotropin-releasing hormone antagonists on steroidogenesis in human granulosa lutein cells. Eur J Endocrinol 144 (2001) 677-685
30. Lin Y., Kahn J.A., and Hillensjö T. Is there a difference in the function of granulosa-luteal cells in patients undergoing in-vitro fertilization either with gonadotrophin-releasing hormone agonist or gonadotrophin-releasing hormone antagonist?. Hum Reprod 14 (1999) 885-888
31. Minaretzis D., Alper M.M., Oskowitz S.P., Lobel S.M., Mortola J.F., and Pavlou S.N. Gonadotropin-releasing hormone antagonist versus agonist administration in women undergoing controlled ovarian hyperstimulation: cycle performance and in vitro steroidogenesis of granulosa-lutein cells. Am J Obstet Gynecol 172 (1995) 1518-1525
32. Smith P.F., Frawley L.S., and Neill J.D. Detection of LH release from individual pituitary cells by the reverse hemolytic plaque assay: estrogen increases the fraction of gonadotropes responding to GnRH. Endocrinology 115 (1984) 2484-2486
33. Lobo R.A., Granger R., Goebelsmann U., and Mishell Jr. D.R. Elevations in unbound serum estradiol as a possible mechanism for inappropriate gonadotropin secretion in women with PCOS. J Clin Endocrinol Metab 52 (1981) 156-158
34. Xia Y.X., Weiss J.M., Polack S., Diedrich K., and Ortmann O. Interactions of insulin-like growth factor-I, insulin and estradiol with GnRH-stimulated luteinizing hormone release from female rat gonadotrophs. Eur J Endocrinol 144 (2001) 73-79
35. Weiss J.M., Chi M., Polack S., Diedrich K., and Ortmann O. Interactions of insulin-like growth factors and estradiol in rat pituitary gonadotrophs. Growth Factors 21 (2003) 61-69
36. Weiss J.M., Polack S., Treeck O., Diedrich K., and Ortmann O. Regulation of GnRH I receptor gene expression by the GnRH agonist triptorelin, estradiol, and progesterone in the gonadotroph-derived cell line alphaT3-1. Endocrine 30 (2006) 139-144
37. Griesinger G., Diedrich K., Tarlatzis B.C., and Kolibianakis E.M. GnRH-antagonists in ovarian stimulation for IVF in patients with poor response to gonadotrophins, polycystic ovary syndrome, and risk of ovarian hyperstimulation: a meta-analysis. Reprod Biomed Online 13 (2006) 628-638
38. Orvieto R. Can we eliminate severe ovarian hyperstimulation syndrome?. Hum Reprod 20 (2005) 320-322